PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets… Read more
PlexBio Co., Ltd. (6572) - Net Assets
Latest net assets as of June 2025: NT$327.65 Million TWD
Based on the latest financial reports, PlexBio Co., Ltd. (6572) has net assets worth NT$327.65 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$524.37 Million) and total liabilities (NT$196.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$327.65 Million |
| % of Total Assets | 62.48% |
| Annual Growth Rate | -13.3% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.58 |
PlexBio Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how PlexBio Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PlexBio Co., Ltd. (2020–2024)
The table below shows the annual net assets of PlexBio Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$374.41 Million | -11.78% |
| 2023-12-31 | NT$424.40 Million | -11.48% |
| 2022-12-31 | NT$479.43 Million | -10.27% |
| 2021-12-31 | NT$534.32 Million | -19.35% |
| 2020-12-31 | NT$662.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PlexBio Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30637800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.04 Billion | 276.83% |
| Other Components | NT$614.27 Million | 164.06% |
| Total Equity | NT$374.41 Million | 100.00% |
PlexBio Co., Ltd. Competitors by Market Cap
The table below lists competitors of PlexBio Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
$8.39 Million |
|
Beauty Skin Corp.
KQ:406820
|
$8.39 Million |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
$8.39 Million |
|
HeveaBoard Bhd
KLSE:5095
|
$8.39 Million |
|
LBT Innovations Ltd
AU:LBT
|
$8.39 Million |
|
Apollo Silver Corp
OTCQB:APGOF
|
$8.38 Million |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
$8.38 Million |
|
Solueta Co Ltd
KQ:154040
|
$8.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PlexBio Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 424,401,000 to 374,412,000, a change of -49,989,000 (-11.8%).
- Net loss of 61,634,000 reduced equity.
- Other comprehensive income increased equity by 34,399,000.
- Other factors decreased equity by 22,754,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-61.63 Million | -16.46% |
| Other Comprehensive Income | NT$34.40 Million | +9.19% |
| Other Changes | NT$-22.75 Million | -6.08% |
| Total Change | NT$- | -11.78% |
Book Value vs Market Value Analysis
This analysis compares PlexBio Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.10x to 1.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$6.43 | NT$7.10 | x |
| 2021-12-31 | NT$5.16 | NT$7.10 | x |
| 2022-12-31 | NT$4.63 | NT$7.10 | x |
| 2023-12-31 | NT$4.06 | NT$7.10 | x |
| 2024-12-31 | NT$3.58 | NT$7.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PlexBio Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.13%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.53x
- Recent ROE (-16.46%) is above the historical average (-17.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -21.29% | -139.19% | 0.12x | 1.24x | NT$-207.32 Million |
| 2021 | -24.63% | -105.32% | 0.17x | 1.37x | NT$-185.02 Million |
| 2022 | -11.08% | -27.79% | 0.33x | 1.21x | NT$-101.08 Million |
| 2023 | -13.79% | -35.01% | 0.32x | 1.22x | NT$-100.97 Million |
| 2024 | -16.46% | -48.13% | 0.22x | 1.53x | NT$-99.08 Million |
Industry Comparison
This section compares PlexBio Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PlexBio Co., Ltd. (6572) | NT$327.65 Million | -21.29% | 0.60x | $8.39 Million |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |